Cargando…

S279: EFFECT OF VOXELOTOR ON CEREBRAL PERFUSION AND CEREBRAL OXYGEN METABOLISM IN ADULT PATIENTS WITH SICKLE CELL DISEASE; THE COVERAGE STUDY

Detalles Bibliográficos
Autores principales:	Konté, Kadère, Afzali-Hashemi, Liza, Baas, Koen, Schrantee, Anouk, Nur, Erfan, Nederveen, Aart, Biemond, Bart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428500/ http://dx.doi.org/10.1097/01.HS9.0000968028.53603.b7

Ejemplares similares

P1421: THE EFFECT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION ON CEREBRAL PERFUSION AND OXYGEN METABOLISM IN PATIENTS WITH SICKLE CELL DISEASE
por: Afzali-Hashemi, Liza, et al.
Publicado: (2023)

S278: CEREBRAL HEMODYNAMICS AND OXYGEN METABOLISM IN PATIENTS WITH MILD AND SEVERE SICKLE CELL DISEASE AND THALASSEMIA
por: Afzali-Hashemi, Liza, et al.
Publicado: (2023)

P1450: VOXELOTOR TREATMENT LEADS TO IMPROVED VIABILITY OF SICKLE ERYTHROCYTES
por: Konté, Kadère, et al.
Publicado: (2023)

Impairment of Cerebrovascular Hemodynamics in Patients With Severe and Milder Forms of Sickle Cell Disease
por: Afzali-Hashemi, Liza, et al.
Publicado: (2021)

Assessment of functional shunting in patients with sickle cell disease
por: Afzali-Hashemi, Liza, et al.
Publicado: (2022)

Incidence of Sars-COV-2 Infection in Sickle Cell Patients Presenting with a Painful Crisis, a 12 Month Prospective Cohort Study
por: Konté, Kadère, et al.
Publicado: (2021)

Incidence of SARS‐COV‐2 infection in sickle cell patients presenting with a painful crisis: A 12‐month prospective cohort study
por: Konté, Kadère, et al.
Publicado: (2021)

The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease
por: Minniti, Caterina P., et al.
Publicado: (2021)

P1465: SAFETY AND EFFICACY OF APOTRANSFERRIN INFUSION IN PATIENTS WITH BETA-THALASSEMIA INTERMEDIA, THE AIM STUDY
por: Konté, Kadère, et al.
Publicado: (2023)

Cerebral oxygen metabolism in adults with sickle cell disease
por: Václavů, Lena, et al.
Publicado: (2020)

Voxelotor: A Ray of Hope for Sickle Disease
por: AlDallal, Salma M
Publicado: (2020)

Quantification of cerebral perfusion and cerebrovascular reserve using Turbo‐QUASAR arterial spin labeling MRI
por: Zhao, Moss Y., et al.
Publicado: (2019)

Patient perception of voxelotor treatment benefit in sickle cell disease
por: Idowu, Modupe, et al.
Publicado: (2022)

Practical Guidance for the Use of Voxelotor in the Management of Sickle Cell Disease
por: Barriteau, Christina M, et al.
Publicado: (2022)

Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease
por: Yenamandra, Avani, et al.
Publicado: (2020)

Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease
por: Telfer, Paul, et al.
Publicado: (2018)

Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe
por: Ferlis, Mica, et al.
Publicado: (2022)

Modeling the public health impact of voxelotor in the management of sickle cell disease in France
por: Galacteros, Frédéric, et al.
Publicado: (2023)

S118: LONG-TERM SAFETY AND EFFICACY OF VOXELOTOR FOR PATIENTS WITH SICKLE CELL DISEASE: RESULTS FROM AN OPEN-LABEL EXTENSION OF THE PHASE 3 HOPE TRIAL
por: Achebe, M, et al.
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease
por: Hutchaleelaha, Athiwat, et al.
Publicado: (2019)

Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor
por: Glaros, Alexander K., et al.
Publicado: (2021)

Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine
por: Migotsky, Michael, et al.
Publicado: (2022)

5610417 IN-VITRO REAL-TIME OBSERVATION OF MODERATE SICKLING KINETICS IN SICKLE ERYTHROCYTES TREATED BY VOXELOTOR UNDER MONOTONIC AND CYCLIC HYPOXIA
por: Qiang, Y.Q., et al.
Publicado: (2023)

Model‐informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma
por: Savic, Radojka M., et al.
Publicado: (2022)

More to voxelotor than meets the eye?
por: Bovino, Robert C., et al.
Publicado: (2022)

PB2516: ACTIGRAPHY IMPROVEMENT WITH VOXELOTOR (ACTIVE) STUDY: IMPACT OF VOXELOTOR ON PHYSICAL ACTIVITY, FATIGUE, AND SLEEP QUALITY
por: Shah, Nirmish, et al.
Publicado: (2023)

Voxelotor versus other therapeutic options for sickle cell disease: Are we still lagging behind in treating the disease?
por: Tayyaba Rehan, Syeda, et al.
Publicado: (2022)

Patient-Reported Experiences in Voxelotor-Treated Children and Adults with Sickle Cell Disease: A Semistructured Interview Study
por: Brown, Clark, et al.
Publicado: (2023)

5559749 A MULTICENTER, RETROSPECTIVE STUDY ON REAL-WORLD EXPERIENCE OF PATIENTS WITH SICKLE CELL DISEASE TREATED WITH VOXELOTOR
por: Andemariam, B., et al.
Publicado: (2023)

P1432: PATTERNS OF VOXELOTOR USE IN A MULTICENTER, REAL-WORLD STUDY OF PATIENTS WITH SICKLE CELL DISEASE
por: Andemariam, Biree, et al.
Publicado: (2023)

Sinusoidal CO(2) respiratory challenge for concurrent perfusion and cerebrovascular reactivity MRI
por: Vu, Chau, et al.
Publicado: (2023)

Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment
por: Preston, Richard A., et al.
Publicado: (2020)

Voxelotor Modulates the Analgesic Effect of Certain Opioids
por: Ballas, Samir K.
Publicado: (2021)

P1485: A MULTICENTER, RETROSPECTIVE STUDY ON REAL-WORLD EXPERIENCE OF PATIENTS WITH SICKLE CELL DISEASE TREATED WITH VOXELOTOR
por: Andemariam, B., et al.
Publicado: (2022)

Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease
por: Alshurafa, Awni, et al.
Publicado: (2022)

The age-dependent effects of a single-dose methylphenidate challenge on cerebral perfusion in patients with attention-deficit/hyperactivity disorder
por: Schrantee, A, et al.
Publicado: (2016)

Cerebral perfusion in sepsis
por: Burkhart, Christoph S, et al.
Publicado: (2010)

More Unnecessary Imaginary Worlds – Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease
por: Langley, Paul C
Publicado: (2020)

Model‐informed drug development of voxelotor in sickle cell disease: Exposure‐response analysis to support dosing and confirm mechanism of action
por: Green, Michelle L., et al.
Publicado: (2022)

Cerebral Perfusion and Cerebral Autoregulation after Cardiac Arrest
por: van den Brule, J. M. D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_v18duqartors1t518eqf75ui1s